Shares of Stevanato Group S.p.A. (NYSE:STVN – Get Free Report) have received an average rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company.
Several research firms have weighed in on STVN. Morgan Stanley began coverage on Stevanato Group in a research report on Monday, December 1st. They set an “equal weight” rating and a $24.00 price target for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stevanato Group in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Jefferies Financial Group set a $17.50 target price on shares of Stevanato Group in a report on Tuesday, February 10th.
Check Out Our Latest Stock Report on STVN
Institutional Inflows and Outflows
Stevanato Group Stock Down 1.9%
Shares of NYSE STVN opened at €15.99 on Wednesday. The firm’s 50-day moving average is €18.62 and its two-hundred day moving average is €22.16. The company has a market capitalization of $4.84 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 1.34 and a beta of 0.58. Stevanato Group has a 12-month low of €13.91 and a 12-month high of €28.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.89 and a quick ratio of 1.30.
About Stevanato Group
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
Featured Articles
- Five stocks we like better than Stevanato Group
- The gold chart Wall Street is terrified of…
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
